Back
Speaker illustration

undefined undefined undefined

Presentations Articles

Gender differences in cardiac transthyretin amyloidosis: diagnostic gap in female patients

Event: ESC Congress 2025

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Novel treatment approaches in heart failure and cardiomyopathies

Access
Like
Thumbnail

Impact of rhythm control in wild-type transthyretin cardiac amyloidosis and atrial fibrillation: a retrospective analysis

Event: ESC Congress 2025

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Novel treatment approaches in heart failure and cardiomyopathies

Access
Like
Thumbnail

Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy

Event: ESC Congress 2024

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Cardiac amyloidosis, sarcoidosis, and inflammation

Access
Like
Thumbnail

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Event: ESC Congress 2024

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Cardiac amyloidosis, sarcoidosis, and inflammation

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources